Investment
Features
FeesSafety
Academy
More
Pluang+

Home Bancorp to release Q3 2026 earnings on Oct 19, followed by a conference call on Oct 20

Company Fundamentals
05 Oct 2026
PRNewsWire
View Source
Neutral
Home Bancorp to release Q3 2026 earnings on Oct 19, followed by a conference call on Oct 20

Home Bancorp, the parent company of Home Bank, will announce its earnings for the third quarter ending September 30, 2026, after market close on October 19. The company will host a conference call on October 20 at 10:30 a.m. CDT to discuss the results, led by top executives including the CEO and CFO. The earnings release and call details will be available on the company’s investor relations website. This update is important for investors tracking the bank's financial performance and strategic outlook.

Home Bancorp's upcoming Q3 2026 earnings announcement provides context for financial sector activity. For readers following Financials, here is Pluang's market snapshot as of Oct 06, 2026 02:42 WIB: Among 85 priced US Financial stocks, 60 rose and 24 fell today. Gemini Space Station Inc (GEMI) gained 2.57% to USD 4.79 with a typical hold time of 14 days and a buy-heavy order activity of 68%. In contrast, Riot Platforms Inc (RIOT) dropped 2.53% to USD 19.23, held typically for 16 days, with 91% buy orders. Visa Inc (V) rose 2.44% to USD 369.45 but saw 73% sell orders and a much longer typical hold time of 115 days.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
1 hour ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
2 hours ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
3 hours ago
Near Protocol (NEAR) jumps nearly 6% amid $280K short liquidations on major exchanges

Near Protocol (NEAR) jumps nearly 6% amid $280K short liquidations on major exchanges

Near Protocol (NEAR) surged to $5.28, rising 5.94% within four hours on October 6, driven by $280,000 worth of short position liquidations across Binance, Bybit, and OKX. The price climbed from $4.98 during this period and showed a 7.14% gain over th...

Market News
Bullish
4 hours ago
Class action lawsuit filed against Alphabet over misleading statements on Gemini 3.5 Pro delays

Class action lawsuit filed against Alphabet over misleading statements on Gemini 3.5 Pro delays

A class action lawsuit has been filed against Alphabet Inc. for allegedly making false and misleading statements about the performance and launch delays of its Gemini 3.5 Pro product between May 19 and July 16, 2026. The lawsuit claims these misstate...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App